---
document_datetime: 2023-09-21 21:39:51
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hemangiol-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: hemangiol-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.0804775
conversion_datetime: 2025-12-24 02:34:48.665538
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Hemangiol

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0023               | Transfer of Marketing Authorisation                                                       | 14/12/2022                          | 10/01/2023                                  | SmPC, Labelling and PL           |           |
| IA/0022              | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the | 26/04/2022                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10250 /202104 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/01/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0019             | Update of section 4.4 of the SmPC to amend the existing warning on hypoglycaemia and of the Package Leaflet to amend the existing warnings on hypotension/bradycardia and hypoglycaemia following the completion of a Drug Utilisation Study (DUS) performed in Germany and France to evaluate off-label use and effectiveness of RMM in a real-life clinical setting (MEA 002); the Annex II to the Opinion is updated in accordance. In addition, editorial amendments are made to section 4.4 of the SmPC and to the Package Leaflet. The RMP version 3.5 has also been agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 28/11/2019 | 18/11/2020 | SmPC and PL                      | Propranolol can aggravate hypoglycaemia in children, especially during fasting period (e.g. poor oral food intake, infection, vomiting), when glucose demands are increased (cold, stress, infections), or in case of overdose. Prescribers should inform carers/parents on the risk of serious hypoglycaemia that remains equally prominent throughout the whole treatment period and emphasize the need to respect the dosing recommendations. Carers should be provided guidance on how to recognise the clinical signs of hypoglycaemia in order to immediately treat and prevent life-threatening situations, contact a doctor or go straight to hospital, and discontinue the treatment |
| PSUSA/10250 /201904 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 31/10/2019 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| R/0018              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/11/2018 | 15/01/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10250 /201804 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 15/11/2018 | 11/01/2019 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                     |            |            |                 | PSUSA/10250/201804.               |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IA/0016             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                       | 24/07/2018 | n/a        |                 |                                   |
| IAIN/0015           | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking | 04/07/2018 | n/a        |                 |                                   |
| IA/0014             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                       | 23/05/2018 | 15/01/2019 | Annex II and PL |                                   |
| N/0013              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                    | 14/03/2018 | 15/01/2019 | Labelling       |                                   |
| PSUSA/10250 /201704 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                            | 30/11/2017 | n/a        |                 | PRAC Recommendation - maintenance |
| PSUSA/10250 /201604 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                            | 01/12/2016 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0011           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                          | 25/10/2016 | n/a        |                 |                                   |
| PSUSA/10250 /201510 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                            | 13/05/2016 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0008             | B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms            | 07/01/2016 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0007             | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                                                                                                                                             | 07/01/2016   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004             | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                                                                           | 26/11/2015   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10250 /201504 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                                                                                                                                                                                                                     | 06/11/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/10250 /201410 | Periodic Safety Update EU Single assessment - propranolol (centrally authorised product)                                                                                                                                                                                                                                                                                     | 07/05/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0005             | B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold                                                                                                                                                                                                                                                    | 30/04/2015   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0002             | Update of section 4.8 of the SmPC to reflect the number of studies and the number of patients included in the safety database analysed, following completion of 2 safety studies one of which to investigate long term effects including effect on growth. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/09/2014   | 03/07/2015 | SmPC        | The MAH has submitted the updated efficacy and safety report of the pivotal study 201 as well as the results of a small study conducted in France (study 301). The provided data were fully in agreement with the primary analysis and they not change the overall benefit-risk balance of Hemangiol in the authorised indication. This update did not lead to a change in the frequency or in the list of adverse events. |
| IB/0001/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                           | 10/07/2014   | 03/07/2015 | SmPC, Annex |                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   | II, Labelling and PL   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|